Table 9.

Association of Demographic and Clinical Characteristics with Infliximab Treatment Persistency

Variable	P*	Hazard ratio	95% CI
			Lower	Upper
Immunosuppressives	.015	0.60	0.40	0.91
Gender	.037	1.47	1.02	2.11
Race†	.077	0.64	0.39	1.05
Pretreatment	.238	1.24	0.87	1.76
Age	.541	1.00	0.99	1.02

^*P based on Cox's proportional hazard regression analysis.

^†Caucasian versus other.

CI

confidence interval

.